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A B S T R A C T
The processing of novel stimuli is known to take place in the hippocampus and frontal cortex, and is influenced
by the cholinergic system. This ability is crucial to help detect changes in the environment and adapt behaviour
accordingly. Previous research has shown that acetylcholine (ACh) can interact with serotonin (5-HT) at the
hippocampal level, which may have consequences for cognitive functioning. However, little is known about the
exact nature of this ACh and 5-HT interaction as well their possible interactive effects on novelty processing.
We investigated the interactive role of ACh and 5-HT in novelty processing in healthy young participants.
Levels of these neurotransmitters were manipulated with the muscarinic M1 antagonist biperiden, and with
acute tryptophan depletion (ATD). Participants received either placebo, biperiden, ATD, or a combination of
both in a double-blind cross-over design. Auditory event-related potentials (ERPs) were recorded while a novelty
oddball task was presented.
Our results showed that biperiden affected ERP components considered to reflect attentional mechanisms; it
increased the P50 amplitude and decreased that of the P200. Furthermore, a decrease of N100 amplitude by ATD
was reversed by biperiden. The treatments did not affect the mismatch negativity (MMN) component, which is
elicited when a deviant stimulus is presented in a sequence of repetitive stimuli. Importantly, biperiden
decreased the amplitude of the ERP component related to novelty processing (P3a).
The current study's results did not reveal an interactive effect of ACh and 5-HT on novelty processing.
However, the data do suggest that ACh is involved in novelty processing and that it influences basic stimulus
processing, without affecting sound-discrimination accuracy.
1. Introduction
In everyday life it is essential to appropriately and efficiently
process novel stimuli and events, as well as to distinguish them from
known stimuli. The novelty response is elicited when a stimulus is new,
unexpected or unpredictable, and it can be visualized measuring the
event-related potential (ERP) component P3a [1]. This component, also
called novelty P3, can be elicited by both active and passive tasks such
as oddball tasks. The novelty P3 reaches maximal amplitude at frontal
and central midline electrode positions and peaks around 250–300 ms
after onset of a stimulus [2,3]. It is thought that the novelty P3 is
generated by the frontal lobe and hippocampus [4–7].
A related ERP is the mismatch negativity (MMN), an auditory ERP
that is generated by the brains automatic response to a discriminable
auditory change. This component reflects an automatic process that
detects changes in ongoing auditory stimulation [2]. The MMN is
generated in both auditory cortices, where a change detection process
takes place unconsciously. This information is then transferred to the
frontal cortex where the information may be perceived consciously [8].
The MMN is obtained by extracting the ERP of standard stimuli from
deviant stimuli and can be seen 150–250 ms after stimulus onset [9].
The cholinergic system is involved in cognitive processes such as
memory and attention [10]. More specifically it is known that
degeneration of cholinergic neurons in the basal forebrain lead to
memory and other cognitive problems [11]. Cholinergic challenges
have widely been used to mimic memory impairments in healthy
volunteers and to test the effectiveness of possible treatments for
memory impairment [12]. The role of acetylcholine (ACh) is associated
with different cognitive processes, with some suggesting it is involved
in learning and memory [e.g., [13]], whereas others suggest a role of
ACh in attentional processes [e.g., [14]]. Studies using scopolamine as a
cholinergic antagonist showed involvement of ACh in novelty proces-
sing. When using an active oddball task after the administration of
scopolamine, the amplitude of the novelty P3 was reduced [15].
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However scopolamine did not affect the MMN component after a
passive oddball task [16].
As scopolamine is a nonselective anticholinergic drug, administra-
tion also leads to central and peripheral side effects; a more selective
drug might be preferable over scopolamine to be used as a deficit
model. Biperiden is a selective muscarinic antagonist that has a more
preferable profile than the traditionally muscarinic antagonist scopola-
mine. Biperiden has a higher affinity for the M1 and M4 muscarinic
receptors compared to the other receptor types [17]. Cholinergic
receptors can be found throughout the body, but the M1 receptor is
mainly located in the cerebral cortex and hippocampus [18]. In line
with this assumption, we found that biperiden impaired verbal memory
performance, but also affected novelty processing [19,20]. Based on
these findings the effects of biperiden have been linked to cognitive
deficits in schizophrenia [e.g., [21]].
Serotonin (5-HT) is also related to learning and memory. A method
that has been used as a model for lowering 5-HT is acute tryptophan
depletion (ATD) [22]. It is presumed that ATD impairs cognition by
lowering central 5-HT levels [23,but see 24] and actually has been
shown to impair long-term memory many times [see [25] for a pooled
analysis]. ATD lowers brain 5-HT levels by depleting tryptophan, a
precursor of 5-HT, but alternative pathways, such as the kynurenine
pathway, might be involved as well [24,26].
Previous animal research showed that ACh and 5-HT interact at an
anatomical and neurochemical level [27,28]. Previous research has
shown that ACh can interact with 5-HT at the hippocampal level,
affecting cognitive functions [29]. However, little is known about the
exact nature of this ACh and 5-HT interaction as well their possible
interactive effects on novelty processing. A recent study combined
biperiden and ATD while measuring EEG and showed interactions in
their effect on the P3a amplitude in relation to an episodic memory
task, suggesting that an impairment in novelty processing led to the
memory impairments seen after especially the biperiden treatment
[30]. However the exact nature of this interaction still remains unclear.
To further investigate the interaction between ACh and 5-HT on
attention and novelty processing biperiden and ATD were combined
in this study.
The aim of the current study was to assess the effects of biperiden,
ATD and a combination of both in a novelty EEG paradigm. The effects
were tested in a mismatch negativity and novelty P3 during a novelty
oddball task. Given the interaction previously shown for P3a amplitude
in an episodic task, we hypothesized that the P3a would be reduced
more after the combined treatment as compared to treatment with
either biperiden or ATD alone.
2. Methods
2.1. Participants
Seventeen healthy participants (7 male, 10 female; mean age of 22.4
years (SD = 3.0, range = 19–29)) completed the experiment, who
were recruited from Maastricht University via advertisements. All
participants had a body mass index between 18.5 and 30 and were in
good health as determined by a screening protocol including a standard
medical questionnaire on physical and mental health, and a medical
examination. This examination included measurements of blood pres-
sure and pulse rate, a resting electrocardiogram (ECG), urine samples
for drug screen and pregnancy test, and blood samples for haematology
and biochemistry.
Participants were excluded in case of past or current cardiac,
hepatic, renal, pulmonary, neurological, gastrointestinal, or haemato-
logical illness; current, past, or having a first-degree relative with
psychiatric illness; pregnancy; lactation; and presence of any sensory or
motor deficits which could be expected to affect test performance.
Furthermore, use of medication other than oral contraceptives, use of
recreational drugs later than 2 weeks before start of the study, and
excessive alcohol consumption (> 20 alcohol beverages per week) also
lead to exclusion from this study.
All participants signed an informed consent form prior to participat-
ing in the study and received a financial reward for their participation.
This study was approved by the Medical Ethics Committee of
Maastricht University and performed in accordance with the 1964
Declaration of Helsinki.
2.2. Treatment and design
In order to induce ATD, participants consumed a protein drink
without tryptophan 5 h before EEG measurements were taken. The
drink consisted of 100 g gelatin (Solugel P) provided by PB Gelatins in
Tessenderlo, Belgium which was mixed with 200 ml tap water. Previous
studies in which an ATD drink with an identical mixture was used, have
shown its impairing effects on cognition [e.g., [31]]. Additionally, it
has consistently been found that this treatment leads to a 70–75%
decrease in human plasma tryptophan levels [31–33]. The placebo
treatment consisted of a drink containing the same composition, with
the addition of 1.21 g L-tryptophan. ATD and placebo drinks had an
identical taste.
One hour before the EEG recording, biperiden hydrochloride
(Akineton®, instant release) was administered orally. Capsules were
purchased from Laboratorio Farmaceutico S.I.T. in Mede, Italy and
contained 2 mg biperiden, which is within the range of recommended
doses for this drug. Former studies have found that 2 mg of orally
administered biperiden impairs cognitive performance in healthy (old-
er) adults [34,35].
The study was carried out according to a double-blind, placebo-
controlled, 4-way cross-over design. The treatment order (biperiden,
ATD, a combination, or placebo) was balanced over 4 test days and
separated by a washout period of at least 7 days. Each participant
received the medication in a unique order.
2.3. Procedure
It should be noted that this study was part of a larger experiment
assessing the interactive role of ACh and 5-HT in cognitive processing
[30]. Only the results of the novelty oddball task are reported here.
After enrolment in the study, the participants first performed a
training session in order to familiarize them with the procedure and
minimize learning effects. The day before a test day, participants were
not allowed to consume alcohol, and on the test day itself caffeine
intake was not allowed.
Each test day started with an assessment of general status and the
participant filling in the questionnaires. Subsequently, participants
received either the ATD protein drink or the placebo drink.
Participants were then allowed read a book or study while they waited.
Three hours after intake of the drink, the capsule containing either
biperiden or a placebo was administered. In the hour following, the
participants were allowed to have a low-protein lunch containing
protein free bread, jam, a tomato, an apple, and some caffeine-free
soda. Participants were prepared for EEG recording and after this hour,
the EEG recording and cognitive testing started.
2.4. EEG recording and stimuli
An EEG cap was used containing 32 electrodes according to the
international 10–20 system (Jasper, 1958). The reference and ground
were placed at the linked mastoids and at the FPz position within the
cap, respectively. Eye movements were detected by horizontal and
vertical electro-oculogram (EOG) recordings. Before electrode attach-
ment, the positions were cleaned with alcohol and slightly scrubbed
with a gel in order to provide an impedance of less than 5 kOhm. Both
EEG and EOG were filtered between 0.01 and 100 Hz and sampled at
1000 Hz.
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In the novelty oddball task, three types of auditory stimuli were
presented while the participants watched a silent cartoon and were
instructed to ignore the stimuli: frequent standard, infrequent deviant
and infrequent novel stimuli. The standard and deviant stimuli
consisted of 750 Hz and 500 Hz tones, respectively, with two upper
harmonic components (1000 and 1500; 1500 and 2250 Hz). The
intensity of the first and second harmonic components was lowered
compared to the fundamental by 3 and 6 dB, respectively. The novel
stimuli contained three stimulus categories of 20 different sounds,
namely human, animal, and mechanical sounds. The infrequent deviant
and novel stimuli were each presented randomly in 12.5% of the trials.
All sounds were presented for a duration of 300 ms with 10-ms rise and
fall times and a 1000 ms onset asynchrony was used. Stimuli were
presented with an average intensity of 70 dB.
2.5. Analysis
2.5.1. EEG analysis
All EEG data were analyzed using BrainVision Analyzer 2.0 (Brain
Products GmhB, Gilching, Germany). Offline, the data were visually
inspected to check for artefacts. EOG activity was filtered out of the
EEG using the data of the VEOG channel and trials in which movement
artefacts occurred were excluded from analysis. The EEG signal was
filtered using a high-pass filter at 1 Hz (12 dB slope) and a low-pass
filter at 30 Hz (12 dB slope). The EEG fragments within an epoch of
100 ms before stimulus onset and 1000 ms after stimulus onset were
averaged to extract the ERP components, using the 100 ms pre-stimulus
as baseline.
For each of the four treatment conditions, averages were calculated
separately for the three stimulus types (standard, deviant, novel). Next,
grand averages were made from which the following obligatory ERP
components were determined: P50 (60–90 ms), N100 (90–140 ms), and
P200 (130–240 ms). Furthermore, difference waves were calculated by
subtracting the averages of the standard stimulus from the averages of
the deviant and novel stimuli types. The grand averages of these
difference waves were used to determine the following components:
MMN (100–190 ms) and P3a (180–300 ms).
2.5.2. Statistical analysis
All data were analyzed using the SPSS for Windows (version 21;
SPSS Inc, Chicago, IL, USA). The Fz, FCz, and Cz electrodes were used
because these channels elicited the largest ERP responses in these types
of tasks [2]. The maximum amplitudes and latencies of the obligatory
P50, N100, and P200 components and those of the MMN and P3a from
the difference waves were analyzed using a 2 × 2× 3 repeated
measures ANOVA. The two-treatment conditions biperiden (2 levels:
yes or no biperiden) and ATD (2 levels: yes or no ATD) and Electrode (3
levels: Fz, FCz, and Cz) were entered as within subject factors. In case of
interaction effects, simple effects were examined. A significance level of
α = .05 was used throughout and Bonferroni correction was used for
post hoc tests.
3. Results
One participant was excluded from analysis due to incomplete data.
Sixteen participants were included in the final analysis.
Overall, latencies were not found to be significantly affected by the
treatment conditions. Some Treatment x Electrode effects were found
randomly throughout the data, which were considered spurious and
were not reported on in the following section.
3.1. Obligatory ERP responses
Fig. 1 shows that the deviant and novel sounds elicited larger
amplitudes than standards in the placebo condition, in line with normal
findings in the novelty oddball paradigm. Fig. 2 shows the effects of the
four treatment conditions on P50, N100 and P200 amplitudes of the
standard stimuli.
The 2 × 2× 3 analysis revealed that treatment with biperiden
significantly increased the P50 amplitude (F(1, 15) = 8.264,
p = 0.012) and decreased the P200 amplitude (F(1, 15) = 5.364,
p = 0.035). ATD treatment did not result in significant effects on the
amplitude of these components (P50 (F(1, 15) = 1.835, p 0.196; P200
(F(1, 15) = 4.326, p = 0.055)), although the latter did show a trend
towards significance. An ATD*biperiden interaction effect was found on
the amplitude of the N100 (F(1, 15) = 6.315, p = 0.024). An analysis
of simple effects revealed that the combination of ATD and biperiden
lead to a significant increase of the N100 amplitude (F(1, 15) = 4.912,
p = 0.043), while this was not the case for participants only treated
with ATD (F(1, 15) = 2.982, p= 0.105). No interaction was found on
the P50 (F(1, 15) = 2.624, p= 0.126) or the P200 (F(1, 15) = 0.198,
p = 0.663).
3.2. Difference waves
In Fig. 3 the difference waves of the placebo group are presented.
Generally, the ERP components in the novel-standard difference wave
have larger amplitudes than those in the deviant-standard difference
wave. Fig. 4 visualizes the effects of the four treatment conditions on
the P3a amplitude of the novel-standard difference score.
None of the treatments significantly affected MMN amplitudes of
the deviant-standard difference scores (ATD (F(1, 15) = 3.493,
p = 0.081); biperiden (F(1, 15) = 1.405), p = 0.254); ATD*biperiden
(F(1, 15) = 0.547, p = 0.471)) or the novel-standard difference scores
(ATD (F(1, 15) = 0.269, p = 0.612; biperiden (F(1, 15) = 0.995,
p = 0.334); ATD*biperiden (F(1, 15) = 0.403, p= 0.535). However,
treatment with biperiden significantly reduced the P3a amplitude of the
novel-standard difference score (F(1, 15) = 15.205, p= 0.001).
Treatment with ATD did not significantly change P3a amplitude (F(1,
15) = 2.164, p = 0.162) nor was an ATD*biperiden interaction effect
evident (F(1, 15) = 1.047, p= 0.322). No significant results were
found for the P3a amplitude of the deviant-standard difference score
(ATD (F(1, 15) = 1.113, p = 0.308); biperiden (F(1, 15) = 4.542,
p = 0.050); ATD*biperiden (F(1, 15) = 0.919, p = 0.353), although
treatment with biperiden did result in a trend towards significance.
4. Discussion
Based on the interaction of ACh and 5-HT on cognitive functioning
we investigated whether such an interaction also exists in relation to
human novelty processing. We showed that biperiden, but not ATD,
Fig. 1. ERP responses to the standard, deviant, and novel stimuli of the placebo condition
(shown here: Cz electrode). Generally, deviant and novel sounds elicited larger
amplitudes than standards.
S. Caldenhove et al. Behavioural Brain Research 331 (2017) 199–204
201
dampened the processing of novel sounds. This was reflected by a
reduced amplitude of the P3a component, the novelty response of the
brain. None of the treatments had an effect on the MMN, a component
related to sound-discrimination accuracy and sensory memory. Basic
stimulus processing was assessed by measuring the P50, N100 and P200
components. We found that biperiden increased the amplitude of the
P50 and N100 peaks, whereas P200 amplitude was decreased. An
interaction effect was found only on the N100, but not on any of the
other recorded ERP signals. These data suggest that M1 antagonism
affects basic stimulus processing and leads to a reduction in novelty
processing, and that there is neither an effect, nor an interaction with 5-
HT.
4.1. P3a
In this study, biperiden significantly reduced P3a amplitude, while
treatment with ATD did not. Our findings corroborate the notion that
ACh is involved in attentional processes [14]. By lowering ACh levels,
the neural response to novel sounds decreases. This is in line with the
findings of Borghans and colleagues [30], who found disrupted novelty
processing after biperiden in an episodic memory task.
Like biperiden, scopolamine is a muscarinic cholinergic receptor
antagonist. Scopolamine is considered the golden standard for inducing
memory deficits and therefore, it has been used more often than
biperiden to study the role of ACh in memory, including novelty
processing. After treatment with scopolamine, several studies have
shown a reduced amplitude of the novelty P3 [15,36–39,but see 40].
However, these studies used an active novelty oddball task, whereas
here a passive task was used. In active oddball tasks participants have to
respond to target stimuli, requiring more attentional effort. This
generally elicits a parietal P3b peak linked to context updating and
working memory function, instead of the frontocentral P3a reflecting
novelty and attentional processing [41,42].
Using a passive oddball paradigm, Klinkenberg, Blokland, Riedel
and Sambeth [20] studied the effects of biperiden and rivastigmine, the
latter increasing ACh levels, on auditory ERPs like the P3a in healthy
young volunteers. In contrast with their hypothesis, biperiden did not
affect the P3a. However, treatment with rivastigmine did enhance P3a
amplitude, which was reversed by biperiden. The authors suggest that
the P3a may not be influenced by drugs acting on M1 receptors, but
rather on another cholinergic receptor, i.e., M2–M5 or nicotinic
receptors. As scopolamine is not specific for the M1 receptor, its actions
on the P3a can also be explained using this line of reasoning. On the
other hand, our results do point to an involvement of M1-receptors in
the processing of novel sounds, since biperiden reduced P3a amplitude.
We expected ATD to also affect the novelty P3, as previous studies
with ATD have shown to impair cognitive processes by lowering central
levels of 5-HT [43,44,e.g.,45]. Unfortunately, not much literature exists
on the effects of ATD on the P3a, specifically. One study by Ahveninen
and colleagues [46] measured the effects of tryptophan depletion on
EEG and MEG responses, but did not find an effect on the P3a.
However, the paradigm used in their study was different from the
novelty oddball paradigm and was not geared towards eliciting robust
P3a responses, but rather towards limiting N100/N200b contamination
of the MMN response. It could be disputed whether ATD is an effective
method for lowering 5-HT neurotransmission [24], or whether it
mediates another chemical process in the brain. It is beyond the scope
of this paper discussing the possible mechanism of action of ATD here.
4.2. MMN
In line with our expectations, no effect was found of biperiden on
the MMN. ATD also did not affect this component. The auditory MMN is
considered to be an index of sound-discrimination accuracy and
auditory sensory memory [47]. Previous EEG studies in which a passive
Fig. 2. Effects of the treatment conditions on the P50, N100 and P200 amplitude (shown here: Cz electrode, means + SEM). Left) Biperiden increased P50 amplitude (p= 0.012);
Middle) Biperiden increased N100 amplitude (p = 0.007) and the ATD*biperiden interaction increased N100 amplitude as well (p = 0.024) Right) Biperiden decreased P200 amplitude
(p= 0.035).
Fig. 3. Deviant-standard and novel-standard difference waves of the placebo condition
(shown here: Cz electrode). The MMN and P3a components of the deviant-standard
difference score were smaller in amplitude than the MMN and P3a components of the
novel-standard difference score.
Fig. 4. Effects of the treatments conditions on P3a amplitude of the novel-standard
difference score (shown here: Cz electrode (means + SEM). Biperiden reduced P3a
amplitude (p = 0.001).
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oddball task was used have found inconsistent results on the MMN after
using scopolamine [16,48]. After the administration of biperiden the
MMN was not affected [20].
Contrary to our hypothesis, the current study's results did not show
ATD to affect the MMN. Previous studies that applied ATD have found
the MMN to be modulated by a 5-HT decrease [49,50], although the
authors do report that the MMN has overlapping subcomponents
reflecting different phases of detection and orienting to novel stimuli.
Additionally, Kahkonen, Makinen, Jaaskelainen, Pennanen, Liesivuori
and Ahveninen [50] explained that the enhancement of MMN seen after
ATD in their study could be the result of confounding effects of N1
modulation. The MMN increase would then actually be an enhanced N1
response, and not a genuine MMN increase.
4.3. Obligatory responses
Similar to the effects on novelty processing, it seems that ACh has a
role in modulating the processes which are related to the obligatory
responses, while 5-HT does not. Our results showed that biperiden
increased the amplitude of the P50 peak, decreased the P200 ampli-
tude, and reversed a decrement in the N100 amplitude leading to a
larger amplitude of the N100, with no statistically significant effects of
ATD. The P50, N100, and P200 components reflect pre-attentive, early
attentive, and late attentive processing mechanisms, respectively
[51,52].
The majority of studies that have used passive or active oddball
paradigms using scopolamine [15,38,39,48] have not found effects on
the N100 and/or P200 amplitude, except for Curran and colleagues
[36] who showed that scopolamine decreased the N100 and P200
amplitudes. Klinkenberg and colleagues [20], who used biperiden in a
passive oddball task, also did not find effects on the N100 and P200
amplitudes. Effects of drugs on the P50 have rarely been investigated;
however, the existing literature is in line with our findings [20,48]. It
should be noted that differences exist between the aforementioned
studies with regard to i.e., recording methods, data analysis, drug
dosage, and means of administration. For this reason, it is difficult to
directly compare the previous study's results to our results. The study by
Klinkenberg and colleagues [20] is most comparable to the current
study. While they have not found effects of biperiden on the N100 and
P200, it was able to reverse an enhanced P3a amplitude. It could be
possible that biperiden has a different effect on early and late
attentional mechanisms. This pattern is also evident in our data, since
we found that biperiden increased the P50 and N100 (i.e. early
attentive) amplitudes and decreased the P200 and P3a (i.e. late
attentive) amplitudes.
The exact role of 5-HT in attentional processes has yet to be
unravelled. There are indications that 5-HT is related to learning and
memory processes [25,53], but the role of 5-HT on the neural correlates
of early attentional processes has rarely been investigated. Similar to
this study's results, a number of EEG studies using other methods of
ATD to examine auditory evoked potentials have not been able to find
effects of lowering central serotonergic levels on the P50 [54], or the
N100/P200 [55,56]. However, evidence also exists that shows ATD
does affect the P50 and N100 by suppressing their amplitudes [57].
4.4. Interactive effects of biperiden and ATD
Little is yet known about the interactive effects of ACh and 5-HT on
cognition. We expected to see an interaction effect of the two
neurotransmitter systems on the novelty P3, based on findings from
previous animal research [see 27,58]. The results did not confirm our
expectations. Additionally, there was no evidence of such an interaction
on other measures of cognitive processing (i.e., P50/N100/P200;
MMN). It may therefore be assumed that in humans, lower levels of
both ACh and 5-HT neurotransmission do not affect processing of novel
stimuli, auditory sensory memory, or any of the early stages of memory
processing to a larger extent than when either neurotransmission of
either ACh or 5-HT is lowered.
Next to the difficulties in translating animal to human research,
there could be a number of reasons why no interaction effect was found
in this study. Firstly, the combination of biperiden and ATD used in the
current study may not have been effective in establishing an interaction
of the two neurotransmitters on cognitive function. Whereas biperiden
blocks ACh neurotransmission by antagonizing the M1 receptor, ATD
likely reduces general brain 5-HT levels and is not receptor-specific
[59]. Even though a selective challenge was combined with a global
challenge in this study, both methods are assumed to act on different
neurotransmitters in the brain. Since both methods have shown to be
able to impair memory performance separately (ATD [e.g.,25,43];
biperiden [e.g.,20,34]) a stronger impairment may have been expected
when combining treatments. For future research, it would be interesting
to look at methods able to lower levels of 5-HT neurotransmission at the
same cortical sites biperiden has its effect.
Secondly, while there is ample evidence for the effectiveness of
biperiden in creating a cholinergic memory deficit [see 60], evidence
for the effects of ATD on 5-HT is still limited. As mentioned previously,
ATD may not have been effective in lowering cortical 5-HT neuro-
transmission. More research on this topic is needed.
Finally, it may also be the case that lowering levels of ACh and 5-HT
at the same time does not cause an interactive effect on the cognitive
functions measured, at least in humans. More studies are needed to
draw a conclusion on this matter.
5. Conclusions
We found that ACh, but not 5-HT is involved in novelty processing
and basic stimulus processing. Participant's sound-discrimination accu-
racy seems to be unaffected by lower central levels of these neuro-
transmitters. No interaction between ACh and 5-HT neurotransmission
was found on the components measured. Since event-related potentials
form an indirect method of measuring treatment effects, an interaction
effect of both neurotransmitter systems cannot be fully excluded.
However, there is ample evidence providing support for the notion
that an interaction between serotonergic and cholinergic systems can be
detected using electrophysiological recording techniques in general
[27][see 27], and more specifically there exists some support for this
interactive role in human EEG studies [e.g., [39]]. More research is
needed to better understand the possible interaction between ACh and
5-HT on attention and memory.
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